Specifically, lower levels of hsa-miR-150-5p and hsa-miR-335-5p and higher levels of MALAT1 and NEAT1 were associated with worse clinicopathologic characteristics, such as higher clinical stage and higher IPI/FLIPI scores and predicted poor prognosis and poor survival rates in NHL patients. The gene discussed is MALAT1; the disease is non-Hodgkin lymphoma.